Pharming Group NV
AEX:PHARM
Pharming Group NV
Intangible Assets
Pharming Group NV
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharming Group NV
AEX:PHARM
|
Intangible Assets
$135.5m
|
CAGR 3-Years
22%
|
CAGR 5-Years
8%
|
CAGR 10-Years
69%
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Uniqure NV
NASDAQ:QURE
|
Intangible Assets
$72.8m
|
CAGR 3-Years
7%
|
CAGR 5-Years
85%
|
CAGR 10-Years
27%
|
|
|
argenx SE
XBRU:ARGX
|
Intangible Assets
$219m
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
178%
|
|
|
Merus NV
NASDAQ:MRUS
|
Intangible Assets
$1.8m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
13%
|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pharming Group NV
Glance View
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
See Also
What is Pharming Group NV's Intangible Assets?
Intangible Assets
135.5m
USD
Based on the financial report for Dec 31, 2025, Pharming Group NV's Intangible Assets amounts to 135.5m USD.
What is Pharming Group NV's Intangible Assets growth rate?
Intangible Assets CAGR 10Y
69%
Over the last year, the Intangible Assets growth was 122%. The average annual Intangible Assets growth rates for Pharming Group NV have been 22% over the past three years , 8% over the past five years , and 69% over the past ten years .
